CanSino Biologics Beheer

Beheer criteriumcontroles 4/4

De CEO CanSino Biologics is Xuefeng Yu, benoemd in Jan2009, heeft een ambtstermijn van 15.92 jaar. De totale jaarlijkse vergoeding van { bedraagt CN¥ 3.97M, bestaande uit 64.1% salaris en 35.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 7.28% van de aandelen van het bedrijf, ter waarde HK$ 821.78M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.8 jaar en 3.2 jaar.

Belangrijke informatie

Xuefeng Yu

Algemeen directeur

CN¥4.0m

Totale compensatie

Percentage CEO-salaris	64.1%
Dienstverband CEO	15.9yrs
Eigendom CEO	7.3%
Management gemiddelde ambtstermijn	6.8yrs
Gemiddelde ambtstermijn bestuur	3.2yrs

Recente managementupdates

Recent updates

CanSino Biologics Inc.'s (HKG:6185) Price Is Right But Growth Is Lacking After Shares Rocket 37%

Nov 11

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

Jun 20

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Apr 07

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Feb 06

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Oct 13

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Sep 07

Analysts Just Made A Major Revision To Their CanSino Biologics Inc. (HKG:6185) Revenue Forecasts

Jul 13

Is CanSino Biologics (HKG:6185) Using Too Much Debt?

Jul 01

We Think CanSino Biologics (HKG:6185) Can Stay On Top Of Its Debt

Mar 15

Analyse CEO-vergoeding

Hoe is Xuefeng Yu's beloning veranderd ten opzichte van CanSino Biologics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-CN¥720m
Jun 30 2024	n/a	n/a	-CN¥867m
Mar 31 2024	n/a	n/a	-CN¥2b
Dec 31 2023	CN¥4m	CN¥3m	-CN¥1b
Sep 30 2023	n/a	n/a	-CN¥1b
Jun 30 2023	n/a	n/a	-CN¥2b
Mar 31 2023	n/a	n/a	-CN¥1b
Dec 31 2022	CN¥5m	CN¥2m	-CN¥909m

Compensatie versus markt: De totale vergoeding ($USD 543.21K ) Xuefeng } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 511.75K ).

Compensatie versus inkomsten: De vergoeding van Xuefeng is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Xuefeng Yu (59 yo)

15.9yrs

Tenure

CN¥3,965,000

Compensatie

Dr. Xuefeng Yu, Ph D, is Co-Founder of CanSino Biologics Inc. since 2009. Dr. Yu serves as an Executive Director at CanSino Biologics Inc. since January 13, 2009 and has served as its Chief Executive Offic...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Xuefeng Yu	Co-Founder	15.9yrs	CN¥3.97m	7.28% HK$ 821.8m
Tao Zhu	Co-Founder	15.9yrs	CN¥4.42m	7.27% HK$ 821.2m
Dongxu Qiu	Co-Founder	15.9yrs	CN¥3.74m	6.94% HK$ 783.4m
Shou-Bai Chao	COO, Deputy GM & Executive Director	6.6yrs	CN¥3.93m	0.028% HK$ 3.1m
Jing Wang	Chief Commercial Officer	3.3yrs	CN¥4.57m	0.0072% HK$ 814.4k
Chunlin Xin	Senior Director of New Technology Department	7.1yrs	geen gegevens	geen gegevens
Yonghui Wu	Vice President of Marketing	no data	geen gegevens	geen gegevens
Jin Cui	Board Secretary	5.8yrs	geen gegevens	geen gegevens
Ming King Chiu	Joint Company Secretary	5.8yrs	geen gegevens	geen gegevens

6.8yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 6185 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Xuefeng Yu	Co-Founder	15.9yrs	CN¥3.97m	7.28% HK$ 821.8m
Shou-Bai Chao	COO, Deputy GM & Executive Director	6.5yrs	CN¥3.93m	0.028% HK$ 3.1m
Jing Wang	Chief Commercial Officer	3.2yrs	CN¥4.57m	0.0072% HK$ 814.4k
George R. Siber	Co-Chair of Scientific Advisory Board	1.9yrs	geen gegevens	geen gegevens
Shan Lu	Member of the Scientific Advisory Board	2.6yrs	geen gegevens	geen gegevens
Shuifa Gui	Independent Non-Executive Director	5.1yrs	CN¥300.00k	geen gegevens
Luis Barreto	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Zhi Xiao	Chairman of Employee Representative Supervisor	less than a year	geen gegevens	geen gegevens
Jianzhong Liu	Independent Non-Executive Director	5.1yrs	CN¥300.00k	0.00040% HK$ 45.2k
Liming Li	Co-Chair of Scientific Advisory Board	1.9yrs	geen gegevens	geen gegevens
Jingren Zhang	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Leung Cheung Yiu	Independent Non-Executive Director	no data	geen gegevens	geen gegevens

3.2yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 6185 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2024/12/27 19:46
Aandelenkoers aan het einde van de dag	2024/12/27 00:00
Inkomsten	2024/09/30
Jaarlijkse inkomsten	2023/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

CanSino Biologics Inc. wordt gevolgd door 19 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Bo Li	BofA Global Research
Lijian Zhao	China International Capital Corporation Limited
Hangci Zheng	China International Capital Corporation Limited

CanSino Biologics Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

COO, Deputy GM & Executive Director recently bought HK$558k worth of stock

Co-Founder recently bought HK$823k worth of stock

Co-Founder recently bought HK$436k worth of stock

High number of new directors

Co-Founder recently bought HK$367k worth of stock

Co-Founder recently bought HK$186k worth of stock

Recent updates

CanSino Biologics Inc. to Report Fiscal Year 2024 Results on Mar 26, 2025

COO, Deputy GM & Executive Director recently bought HK$558k worth of stock

Cansino Biologics Inc. Announces Initiation of Phase I\II Clinical Trial and Completion of First Patient Enrollment in Phase I Clinical Trial for Recombinant Poliomyelitis Vaccine in Indonesia

Cansino Biologics Inc. Announces Acceptance of New Drug Application for DTCP Infant

Co-Founder recently bought HK$823k worth of stock

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Case for the Haemophilus Influenzae Type B Conjugate Vaccine, Freeze-Dried

CanSino Biologics Inc.'s (HKG:6185) Price Is Right But Growth Is Lacking After Shares Rocket 37%

New minor risk - Profitability

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

CanSino Biologics Inc. to Report Q3, 2024 Results on Oct 30, 2024

Co-Founder recently bought HK$436k worth of stock

High number of new directors

Co-Founder recently bought HK$367k worth of stock

Consensus EPS estimates fall by 10%

Co-Founder recently bought HK$186k worth of stock

Co-Founder recently bought HK$377k worth of stock

CanSino Biologics Inc. to Report First Half, 2024 Results on Aug 30, 2024

Should Shareholders Worry About CanSino Biologics Inc.'s (HKG:6185) CEO Compensation Package?

CanSino Biologics Inc., Annual General Meeting, Jun 27, 2024

CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee

Consensus EPS estimates upgraded to CN¥1.19 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Cansino Biologics Inc. Announces Positive Preliminary Results from Phase I Clinical Trials of the Protein-Based Pneumococcal Vaccine

The Consensus EPS Estimates For CanSino Biologics Inc. (HKG:6185) Just Fell Dramatically

Full year 2023 earnings: EPS and revenues miss analyst expectations

CanSino Biologics Inc. to Report Q1, 2024 Results on Apr 30, 2024

Consensus EPS estimates upgraded to CN¥1.04 loss, revenue downgraded

Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine

Full year 2023 earnings: EPS and revenues miss analyst expectations

Is CanSino Biologics (HKG:6185) Weighed On By Its Debt Load?

Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023

CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine

Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine

Cansino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Enrollment for TDCP Adolescent and Adult

CanSino Biologics Inc. Announces Resignation of Xi LUO as Chief Financial Officer

CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case

Third quarter 2023 earnings released

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Analysts Are More Bearish On CanSino Biologics Inc. (HKG:6185) Than They Used To Be

Second quarter 2023 earnings released: CN¥2.82 loss per share (vs CN¥0.44 loss in 2Q 2022)

New minor risk - Share price stability

CanSino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc. Announces CS-2032 Zoster Vaccine Obtains Clinical Trial Approval from Canada

CanSino Biologics Inc. to Report First Half, 2023 Results on Aug 22, 2023

Cansino Biologics Inc. Obtains Clinical Trial Approval

CanSino Biologics Inc., Annual General Meeting, Jun 30, 2023

CanSino Biologics (HKG:6185) Has Debt But No Earnings; Should You Worry?

Full year 2022 earnings released: CN¥3.65 loss per share (vs CN¥7.74 profit in FY 2021)

Consensus EPS estimates fall by 49%

CanSino Biologics Inc. Provides Earnings Guidance for the Period from January 1, 2022 to December 31, 2022

Non-Executive Director recently sold HK$3.4m worth of stock

Does CanSino Biologics (HKG:6185) Have A Healthy Balance Sheet?

Cansino Biologics Inc. Announces Covid-19 Mrna Vaccine Cs-2034 Achieved Positive Interim Data in A Clinical Trial Evaluating the Safety and Immunogenicity of the Heterologous Cs-2034 Booster

CanSino Biologics Inc. Announces Clinical Research Results of A Clinical Trial of Bivalent Recombinant Covid-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation in Adults Aged 18 Years and Above

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

CanSino Biologics Inc. Announces Clinical Research Results of Evaluation of the Safety and Immunogenicity of Two Types of Recombinant Covid-19 Vaccines

Less than half of directors are independent

CanSino Biologics Inc.'s Recombinant Covid-19 Vaccine (Adenovirus Type 5Vector) for Inhalation Approved for Emergency Use in Morocco

Consensus EPS estimates fall by 73%

Consensus revenue estimates fall by 12%

Now 38% undervalued

Third quarter 2022 earnings released

Investor sentiment improved over the past week

CanSino Biologics Inc. to Report Q3, 2022 Results on Oct 28, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

CanSino Biologics Inc.'s (HKG:6185) Share Price Not Quite Adding Up